Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,209,451 papers from all fields of science
Search
Sign In
Create Free Account
MK 927
Known as:
MK 0927
, MK-0927
, MK-927
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
sezolamide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
Uptake and Stereoselective Binding of the Enantiomers of MK-927, a Potent Carbonic Anhydrase Inhibitor, by Human Erythrocytes in Vitro
J. Lin
,
Tsu-Han Lin
,
Haiyung Cheng
Pharmaceutical Research
1992
Corpus ID: 19571372
MK-927 [5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7.7 dioxide], a potent carbonic anhydrase inhibitor…
Expand
1991
1991
Evaluation of a topically administered carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous beagles.
King Tc
,
Gum Gg
,
Gelatt Kn
American Journal of Veterinary Research
1991
Corpus ID: 89247700
A new topically administered anhydrase inhibitor, MK-927, was evaluated for its ocular hypotensive activity in normotensive and…
Expand
1991
1991
Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927.
E. Lippa
,
H. Aasved
,
+7 authors
G. Høvding
A M A Archives of Ophthalmology
1991
Corpus ID: 22084881
The multiple-dose, dose-response curve of MK-927 was studied in a five-center, double-masked, randomized, placebo-controlled…
Expand
1991
1991
Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK‐927 and sezolamide during two‐week ocular administration to normal subjects
T. Buclin
,
J. Biollaz
,
+5 authors
J. Schelling
Clinical pharmacology and therapy
1991
Corpus ID: 37454222
Potential systemic effects of the racemic carbonic anhydrase inhibitor MK‐927 and its S‐enantiomer, sezolamide hydrochloride…
Expand
1990
1990
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
E. Higginbotham
,
M. Kass
,
E. Lippa
,
R. Batenhorst
,
D. Panebianco
,
J. Wilensky
A M A Archives of Ophthalmology
1990
Corpus ID: 12819523
The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients…
Expand
1990
1990
MK-927: a topically active ocular hypotensive carbonic anhydrase inhibitor.
M. F. Sugrue
,
P. Gautheron
,
+6 authors
G. Ponticello
Journal of ocular pharmacology
1990
Corpus ID: 25239848
MK-927 (dl-5,6-dihydro-4-(2-methylpropylamino)-4H-thieno(2,3b)thiopyra n-2-sulfonamide-7,7-dioxide hydrochloride) is a water…
Expand
1990
1990
MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility.
J. Serle
,
J. Lustgarten
,
E. Lippa
,
C. Camras
,
D. Panebianco
,
S. Podos
A M A Archives of Ophthalmology
1990
Corpus ID: 26032375
We investigated the dose-response and reproducibility of the intraocular pressure-lowering effect of MK-927 in ocular…
Expand
1990
1990
The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys.
R. Wang
,
J. Serle
,
S. Podos
,
M. Surgrue
Current Eye Research
1990
Corpus ID: 38787763
MK-927 is a water soluble, potent inhibitor of human carbonic anhydrase (CA) II in vitro. Topical administration of MK-927…
Expand
1989
1989
MK-927: a topically effective carbonic anhydrase inhibitor in patients.
A. Bron
,
E. Lippa
,
+5 authors
H. V. von Denffer
A M A Archives of Ophthalmology
1989
Corpus ID: 44742995
The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time…
Expand
1988
1988
Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor.
E. Lippa
,
H. V. von Denffer
,
H. Hofmann
,
F. Brunner‐Ferber
A M A Archives of Ophthalmology
1988
Corpus ID: 12127893
A three-dose, randomized, double-masked, parallel, placebo-controlled ocular tolerance study was undertaken in 12 healthy, normal…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE